Amolyt Pharma is building on its team’s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma’s portfolio includes AZP-3601, a parathyroid hormone analog for the potential treatment of hypoparathyroidism and AZP-3813, a potential treatment for acromegaly. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.